Prevention of OHSS - dopamine agonists


Por: C. BUSSO, J. GARCIA-VELASCO, R. GOMEZ, C. ALVAREZ, C. SIMON and A. PELLICER

Publicada: 1 jul 2009
Resumen:
Ovarian hyperstimulation syndrome (OHSS) is in iatrogenic complication of ovulation induction, which may seriously affect the patient's health, with 0.1-2.0% of the patients developing severe forms of the syndrome. OHSS signs and symptoms are direct consequences of fluid shift from capillaries to the third space due to increased vascular permeability. The mechanisms of OHSS pathophysiology remain unknown but evidence obtained in animal models prove that vascular endothelial growth factor (VEGF) is directly involved and the inhibition of the VEGF system could prevent OHSS from occurring. Dopamine agonists impede the phosphorylation of the VEGF receptor 2 and reduce the incidence and severity of OHSS with a safe clinical profile. As far as is known, this is the first pathophysiological approach for treatment and prevention of OHSS.

Filiaciones:
C. BUSSO:
 Inst Valenciano Infertilidad Valencia, Valencia 46015, Spain

J. GARCIA-VELASCO:
 Inst Valenciano Infertilidad Madrid, Madrid 28035, Spain

R. GOMEZ:
 Fd6n Inst Valenciano Infertilidad, Valencia 46015, Spain

C. ALVAREZ:
 Inst Valenciano Infertliclad Santiago Chile, Santiago, Chile

:
 Inst Valenciano Infertilidad Valencia, Valencia 46015, Spain

 Ctr Invest Principe Felipe, Valencia, Spain

A. PELLICER:
 Inst Valenciano Infertilidad Valencia, Valencia 46015, Spain

 Valencia Sch Med, Dept Pediat Obstet & Gynaecol, Valencia, Spain
ISSN: 14726483





REPRODUCTIVE BIOMEDICINE ONLINE
Editorial
ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 19 Número: 1
Páginas: 43-51
WOS Id: 000267906000007
ID de PubMed: 19573289

MÉTRICAS